Alibaba Health Information Technology (241) H2 2025 earnings summary

Executive summary

• Revenue grew 13.2% year-over-year to RMB30,598.3 million for FY2025, with net profit up 62.2% to RMB1,432.0 million and adjusted net profit up 35.6% to RMB1,949.7 million.

• Tmall Healthcare Platform and direct sales businesses drove growth, with active user and SKU expansion, and AI integration across operations.

• Gross profit margin improved to 24.3% from 21.8% year-over-year, reflecting operational efficiency and pricing power.

• No final dividend was declared for the year.

Financial highlights

• Revenue: RMB30,598.3 million (+13.2% YoY); Gross profit: RMB7,432.1 million (+26.1% YoY).

• Net profit: RMB1,432.0 million (+62.2% YoY); Adjusted net profit: RMB1,949.7 million (+35.6% YoY).

• Gross profit margin rose to 24.3% (from 21.8%); Adjusted net profit margin improved to 6.4% (from 5.3%).

• Cash and cash equivalents at year-end: RMB2,218.3 million (down from RMB3,490.2 million prior year).

• Basic EPS: RMB8.91 cents (up from RMB6.29 cents); Diluted EPS: RMB8.88 cents.

Outlook and guidance

• Plans to further integrate large language models and AI in healthcare services to optimize efficiency and quality.

• Will continue to expand digital health ecosystem, leveraging online and offline synergies.